This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.

2023 MAA Cohort

We are excited to welcome the following companies to our NHS Market Access Accelerator 2023.

For a more detailed insight into our 2023 programme and cohort, download our brochure (PDF)

Allos is an Oxford-backed startup building an explainable causal AI co-pilot for medical professionals. Causal AI reasons and makes decisions like humans. By analyzing data and identifying the cause-and-effect relationships between variables, Causal AI will help you find precise and actionable strategies to tackle extremely complex scenarios, but in a dynamic, transparent, and bias-free way.


Cardio-Phoenix specialises in the creation of advanced but accessible heart diagnostics. Its goal, a device that is familiar to users, contains game changing diagnostic capabilities that are more widely and easily accessible to healthcare providers and to patients.

LifeYear (Formally Activate)

Activate is a digital therapeutics company tackling the unmet clinical need for personalised cardiometabolic care at scale. By integrating clinical guidelines, behavioral science, real-time data and artificial intelligence, we provide both at-risk patients and clinicians with the tools they need to actively monitor, control, and even reverse cardiometabolic risk factors. Our aim is to reduce hospital admissions and alleviate the burden on healthcare systems by delaying the onset of heart disease and preventing adverse cardiac events across the population.


MyMynd’s digital health platform proactively identifies issues for early intervention and directs targeted support precisely where needed to strengthen resilience and wellbeing. The platform is based around a secure assessment using clinically validated tools.


Oxford Cancer Analytics (OXcan) is on a mission to drastically transform cancer early detection and management to impact billions of lives worldwide. The multidisciplinary team has invented DEcancer, a liquid biopsy blood test developed via cutting-edge proteomics and machine learning that can detect the deadliest cancers early, when they can still be cured.


Trewlink is a complete international medical graduate (IMG) recruitment and retention platform, that makes it easy for NHS Trusts to become ‘IMG Friendly’ and comply with the recently launched ‘Welcoming and Valuing International Medical Graduates’ guidance issued by the BMA, GMC and the NHS.


Frontline clinicians in NHS hospitals deserve better use of hospital medication data. High friction legacy systems work well for immediate treatment. They don’t provide intelligence about stewardship, safe medication usage or key operational challenges. There is clear evidence that medication errors cause patients harm but clinicians don’t have the right tools to manage the problem.

ZiO Health

ZiO Health is a VC-backed medical technology & digital health company that has developed proprietary pocket-sized technology, bringing lab testing to the point of use.

You can keep up-to-date on their progress in our MAA by visiting our LinkedIn page, following us on Twitter, or subscribing to our newsletter.